241 related articles for article (PubMed ID: 17012103)
1. Breast cancer in postmenopausal women with and without hormone replacement therapy: preliminary results of the MISSION study.
Espié M; Mares P; de Reilhac P; Chevallier T; Daurès JP
Gynecol Endocrinol; 2006 Aug; 22(8):423-31. PubMed ID: 17012103
[TBL] [Abstract][Full Text] [Related]
2. Breast cancer incidence and hormone replacement therapy: results from the MISSION study, prospective phase.
Espié M; Daures JP; Chevallier T; Mares P; Micheletti MC; De Reilhac P
Gynecol Endocrinol; 2007 Jul; 23(7):391-7. PubMed ID: 17701770
[TBL] [Abstract][Full Text] [Related]
3. Reduced incidence of distant metastases and lower mortality in 1072 patients with breast cancer with a history of hormone replacement therapy.
Schuetz F; Diel IJ; Pueschel M; von Holst T; Solomayer EF; Lange S; Sinn P; Bastert G; Sohn C
Am J Obstet Gynecol; 2007 Apr; 196(4):342.e1-9. PubMed ID: 17403414
[TBL] [Abstract][Full Text] [Related]
4. Hormone replacement therapy containing progestins and given continuously increases breast carcinoma risk in Sweden.
Olsson HL; Ingvar C; Bladström A
Cancer; 2003 Mar; 97(6):1387-92. PubMed ID: 12627501
[TBL] [Abstract][Full Text] [Related]
5. Incidence of benign and malignant breast disorders in women taking hormones (contraceptive pill or hormonal replacement therapy).
Tzingounis V; Cardamakis E; Ginopoulos P; Argiropoulos G
Anticancer Res; 1996; 16(6C):3997-4000. PubMed ID: 9042326
[TBL] [Abstract][Full Text] [Related]
6. Coronary heart disease and HRT in France: MISSION study prospective phase results.
Mares P; Chevallier T; Micheletti MC; Daures JP; Postruznik D; De Reilhac P
Gynecol Endocrinol; 2008 Dec; 24(12):696-700. PubMed ID: 19172539
[TBL] [Abstract][Full Text] [Related]
7. Hormone replacement therapy and breast cancer risk in Kyushu University Hospital: supporting the Women's Health Initiative study.
Nozaki M; Koera K; Nagata H; Nakano H
J Obstet Gynaecol Res; 2004 Aug; 30(4):297-302. PubMed ID: 15238106
[TBL] [Abstract][Full Text] [Related]
8. Influence of postmenopausal hormone replacement therapy on an estrogen metabolite biomarker of risk for breast cancer.
Alvarez-Vasquez RB; Axelrod D; Frenkel K; Newman MC; Sepkovic DW; Bradlow HL; Zumoff B
Horm Metab Res; 2003 Jun; 35(6):358-61. PubMed ID: 12920658
[TBL] [Abstract][Full Text] [Related]
9. Prognostic characteristics of breast cancer among postmenopausal hormone users in a screened population.
Kerlikowske K; Miglioretti DL; Ballard-Barbash R; Weaver DL; Buist DS; Barlow WE; Cutter G; Geller BM; Yankaskas B; Taplin SH; Carney PA
J Clin Oncol; 2003 Dec; 21(23):4314-21. PubMed ID: 14645420
[TBL] [Abstract][Full Text] [Related]
10. Association of regimens of hormone replacement therapy to prognostic factors among women diagnosed with breast cancer aged 50-64 years.
Daling JR; Malone KE; Doody DR; Voigt LF; Bernstein L; Marchbanks PA; Coates RJ; Norman SA; Weiss LK; Ursin G; Burkman RT; Deapen D; Folger SG; McDonald JA; Simon MS; Strom BL; Spirtas R
Cancer Epidemiol Biomarkers Prev; 2003 Nov; 12(11 Pt 1):1175-81. PubMed ID: 14652277
[TBL] [Abstract][Full Text] [Related]
11. A case-control study of hormone replacement therapy after primary surgical breast cancer treatment.
Ursic-Vrscaj M; Bebar S
Eur J Surg Oncol; 1999 Apr; 25(2):146-51. PubMed ID: 10218456
[TBL] [Abstract][Full Text] [Related]
12. Hormone replacement therapy and some risk factors for breast cancer among Slovenian postmenopausal women.
Cerne JZ; Ferk P; Leskosek B; Gersak K
Climacteric; 2011 Aug; 14(4):458-63. PubMed ID: 21294673
[TBL] [Abstract][Full Text] [Related]
13. Combined estrogen and testosterone use and risk of breast cancer in postmenopausal women.
Tamimi RM; Hankinson SE; Chen WY; Rosner B; Colditz GA
Arch Intern Med; 2006 Jul; 166(14):1483-9. PubMed ID: 16864758
[TBL] [Abstract][Full Text] [Related]
14. [Estrogen replacement therapy and breast cancer].
Bakken K; Alsaker E; Eggen AE; Lund E
Tidsskr Nor Laegeforen; 2005 Feb; 125(3):282-5. PubMed ID: 15702147
[TBL] [Abstract][Full Text] [Related]
15. Case-control study of postmenopausal hormone replacement therapy and endometrial cancer.
Strom BL; Schinnar R; Weber AL; Bunin G; Berlin JA; Baumgarten M; DeMichele A; Rubin SC; Berlin M; Troxel AB; Rebbeck TR
Am J Epidemiol; 2006 Oct; 164(8):775-86. PubMed ID: 16997897
[TBL] [Abstract][Full Text] [Related]
16. Impact of hormone replacement therapy on the histologic subtype of breast cancer.
Zanetti-Dällenbach RA; Krause EM; Lapaire O; Gueth U; Holzgreve W; Wight E
Arch Gynecol Obstet; 2008 Nov; 278(5):443-9. PubMed ID: 18335229
[TBL] [Abstract][Full Text] [Related]
17. Breast cancer risk in the WHI study: the problem of obesity.
Kuhl H
Maturitas; 2005 May; 51(1):83-97. PubMed ID: 15883113
[TBL] [Abstract][Full Text] [Related]
18. Effect of climacteric transition and hormone replacement therapy on body weight and body fat distribution.
Genazzani AR; Gambacciani M
Gynecol Endocrinol; 2006 Mar; 22(3):145-50. PubMed ID: 16835076
[TBL] [Abstract][Full Text] [Related]
19. Hormone replacement therapy and breast density changes.
Harvey J; Scheurer C; Kawakami FT; Quebe-Fehling E; de Palacios PI; Ragavan VV
Climacteric; 2005 Jun; 8(2):185-92. PubMed ID: 16096175
[TBL] [Abstract][Full Text] [Related]
20. Urinary hydroxyestrogens and breast cancer risk among postmenopausal women: a prospective study.
Wellejus A; Olsen A; Tjonneland A; Thomsen BL; Overvad K; Loft S
Cancer Epidemiol Biomarkers Prev; 2005 Sep; 14(9):2137-42. PubMed ID: 16172222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
